JPWO2019191026A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019191026A5
JPWO2019191026A5 JP2020551992A JP2020551992A JPWO2019191026A5 JP WO2019191026 A5 JPWO2019191026 A5 JP WO2019191026A5 JP 2020551992 A JP2020551992 A JP 2020551992A JP 2020551992 A JP2020551992 A JP 2020551992A JP WO2019191026 A5 JPWO2019191026 A5 JP WO2019191026A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
rna virus
keratitis
related disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020551992A
Other languages
Japanese (ja)
Other versions
JP2021519315A (en
JP7242696B2 (en
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/023977 external-priority patent/WO2019191026A2/en
Publication of JP2021519315A publication Critical patent/JP2021519315A/en
Publication of JPWO2019191026A5 publication Critical patent/JPWO2019191026A5/ja
Priority to JP2023035224A priority Critical patent/JP2023071933A/en
Application granted granted Critical
Publication of JP7242696B2 publication Critical patent/JP7242696B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (22)

患者におけるRNAウイルス関連疾患又は病態を、治療、管理、又は予防するための医薬組成物であって、5’-アデノシン二リン酸リボース(ADPR)、又はその薬学的に許容され得る塩、溶媒和物、水和物、互変異性体、立体異性体、同位体分子種、もしくは多形体を含み；ここで、該患者は、RNAウイルス関連疾患又は病態を有しているか、又はそれを発症するリスクがあり；かつ
該RNAウイルス関連疾患又は病態は、RNAウイルスにより引き起こされ、該RNAウイルスは、ヒト呼吸器合胞体ウイルス(HRSV)である、前記医薬組成物。 A pharmaceutical composition for treating, controlling, or preventing RNA virus-related diseases or conditions in patients, 5'-adenosindiphosphate ribose (ADPR), or a pharmaceutically acceptable salt thereof, solvate thereof. Containing substances, hydrates, tautomers, steric isomers, isotope molecular species, or polymorphs; where the patient has or develops an RNA virus-related disease or condition. The pharmaceutical composition at risk; and the RNA virus-related disease or condition is caused by the RNA virus, wherein the RNA virus is a human respiratory syncytial virus (HRSV). 前記RNAウイルス関連疾患又は病態が、眼球上の疾患、結膜炎、角膜炎、角結膜炎、角膜剥離、潰瘍性感染性角膜炎、表層角膜炎、間質性角膜炎、ブドウ膜炎、急性緑内障、眼瞼炎、中耳炎、外耳炎、歯肉炎、粘膜炎、咽頭炎、扁桃炎、鼻炎、副鼻腔炎、喉頭炎、偽膜性喉頭炎、気管炎、気管支炎、細気管支炎、細気管支肺炎、肺炎、喘息憎悪、慢性閉塞性肺疾患の憎悪、肺気腫の憎悪、又は慢性肺疾患の増悪である、請求項1記載の医薬組成物。 The RNA virus-related disease or pathological condition is a disease on the eyeball, conjunctivitis, keratitis, keratitis, keratitis, ulcerative infectious keratitis, superficial keratitis, interstitial keratitis, vulgaris, acute glaucoma, eyelids. Flame, middle ear inflammation, external ear inflammation, gingival inflammation, mucositis, pharyngitis, tonsillitis, nasal inflammation, sinusitis, laryngitis, pseudomembranous laryngitis, tracheitis, bronchiolitis, bronchiolitis, bronchiolitis, pneumonia, asthma The pharmaceutical composition according to claim 1, which is exacerbation, exacerbation of chronic obstructive pulmonary disease, exacerbation of pulmonary emphysema, or exacerbation of chronic lung disease. 前記RNAウイルス関連疾患又は病態が、結膜炎、角膜炎、角結膜炎、咽頭炎、扁桃炎、喉頭炎、鼻炎、副鼻腔炎、気管支炎、細気管支炎、又は肺炎である、請求項2記載の医薬組成物。 The pharmaceutical according to claim 2, wherein the RNA virus-related disease or pathological condition is conjunctivitis, keratitis, keratoconjunctivitis, pharyngitis, tonsillitis, laryngitis, rhinitis, sinusitis, bronchitis, bronchiolitis, or pneumonia. Composition. 前記RNAウイルス関連疾患又は病態が、角膜炎、結膜炎、又は角結膜炎である、請求項3記載の医薬組成物。 The pharmaceutical composition according to claim 3, wherein the RNA virus-related disease or pathological condition is keratitis, conjunctivitis, or keratoconjunctivitis. 前記RNAウイルス関連疾患又は病態が、気管支炎、細気管支炎、又は肺炎である、請求項3記載の医薬組成物。 The pharmaceutical composition according to claim 3, wherein the RNA virus-related disease or pathological condition is bronchitis, bronchiolitis, or pneumonia. 前記RNAウイルス関連疾患又は病態が、咽頭炎、扁桃炎、副鼻腔炎、又は喉頭炎である、請求項3記載の医薬組成物。 The pharmaceutical composition according to claim 3, wherein the RNA virus-related disease or pathological condition is pharyngitis, tonsillitis, sinusitis, or laryngitis. 前記医薬組成物が、局所、経口、非経口、経粘膜、又は吸入の投与経路によって投与される、請求項1記載の医薬組成物。 The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is administered by a local, oral, parenteral, transmucosal, or inhalation route of administration. 前記医薬組成物が、吸入投与により投与される、請求項1記載の医薬組成物。 The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is administered by inhalation administration. 前記局所投与が、前記患者の内部の細胞又は組織表面へ行われる、請求項7記載の医薬組成物。 The pharmaceutical composition according to claim 7, wherein the local administration is performed on the cell or tissue surface inside the patient. 前記局所投与が、エアロゾル化、噴霧、スプレー、経口送達、気管内注入、気管支内、又は気道表面への注入によるものである、請求項9記載の医薬組成物。 The pharmaceutical composition according to claim 9, wherein the topical administration is by aerosolization, spraying, spraying, oral delivery, intratracheal injection, intrabronchial injection, or injection into the airway surface. 前記局所投与が、外部の細胞又は組織表面へ行われる、請求項7記載の医薬組成物。 The pharmaceutical composition according to claim 7, wherein the topical administration is performed on the surface of an external cell or tissue. 前記外部の細胞又は組織表面が、皮膚、目、爪、髪、又は耳の表面である、請求項11記載の医薬組成物。 11. The pharmaceutical composition according to claim 11, wherein the outer cell or tissue surface is the surface of the skin, eyes, nails, hair, or ears. 前記医薬組成物が、静脈内、動脈内、又は導管内注入によって投与される、請求項1記載の医薬組成物。 The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is administered by intravenous, intraarterial, or intraconduit injection. 前記医薬組成物が、液剤、懸濁剤、乳剤、マイクロエマルション、ナノエマルション、坐剤、注腸剤、シロップ剤、エリキシル剤、乾燥粉末エアロゾル、液体エアロゾル、錠剤、又は溶解媒体の形態である、請求項1記載の医薬組成物。 The pharmaceutical composition is in the form of a liquid, suspending, emulsion, microemulsion, nanoemulsion, suppository, enema, syrup, elixir, dry powder aerosol, liquid aerosol, tablet, or dissolution medium. The pharmaceutical composition according to claim 1. 前記溶解媒体が、急速溶解錠剤、フィルム、又はストリップである、請求項14記載の医薬組成物。 The pharmaceutical composition according to claim 14, wherein the dissolving medium is a rapidly dissolving tablet, film, or strip. 前記医薬組成物が、液剤の形態である、請求項14記載の医薬組成物。 The pharmaceutical composition according to claim 14, wherein the pharmaceutical composition is in the form of a liquid preparation. 前記医薬組成物が、他の医薬との組み合わせで投与される、請求項1～16のいずれか一項記載の医薬組成物。 The pharmaceutical composition according to any one of claims 1 to 16, wherein the pharmaceutical composition is administered in combination with another pharmaceutical. 前記他の医薬が、抗ウイルス化合物である、請求項17記載の医薬組成物。 The pharmaceutical composition according to claim 17, wherein the other drug is an antiviral compound. 前記ADPRが、そのナトリウム塩の形態である、請求項1記載の医薬組成物。 The pharmaceutical composition according to claim 1, wherein the ADPR is in the form of a sodium salt thereof. 前記ADPRが、その二ナトリウム塩の形態である、請求項1記載の医薬組成物。 The pharmaceutical composition according to claim 1, wherein the ADPR is in the form of a disodium salt thereof. 前記ADPRが、そのリチウム塩の形態である、請求項1記載の医薬組成物。 The pharmaceutical composition according to claim 1, wherein the ADPR is in the form of a lithium salt thereof. 前記ADPRが、その二リチウム塩の形態である、請求項1記載の医薬組成物。 The pharmaceutical composition according to claim 1, wherein the ADPR is in the form of a dilithium salt thereof.
JP2020551992A 2018-03-27 2019-03-26 Method of using 5'-adenosine diphosphate ribose (ADPR) Active JP7242696B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023035224A JP2023071933A (en) 2018-03-27 2023-03-08 Methods for the use of 5'-adenosine diphosphate ribose (adpr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862648585P 2018-03-27 2018-03-27
US62/648,585 2018-03-27
US201862693021P 2018-07-02 2018-07-02
US62/693,021 2018-07-02
PCT/US2019/023977 WO2019191026A2 (en) 2018-03-27 2019-03-26 Methods for the use of 5'-adenosine diphosphate ribose (adpr)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023035224A Division JP2023071933A (en) 2018-03-27 2023-03-08 Methods for the use of 5'-adenosine diphosphate ribose (adpr)

Publications (3)

Publication Number Publication Date
JP2021519315A JP2021519315A (en) 2021-08-10
JPWO2019191026A5 true JPWO2019191026A5 (en) 2022-04-01
JP7242696B2 JP7242696B2 (en) 2023-03-20

Family

ID=66647439

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020551992A Active JP7242696B2 (en) 2018-03-27 2019-03-26 Method of using 5'-adenosine diphosphate ribose (ADPR)
JP2023035224A Pending JP2023071933A (en) 2018-03-27 2023-03-08 Methods for the use of 5'-adenosine diphosphate ribose (adpr)

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023035224A Pending JP2023071933A (en) 2018-03-27 2023-03-08 Methods for the use of 5'-adenosine diphosphate ribose (adpr)

Country Status (5)

Country Link
US (3) US10946034B2 (en)
EP (2) EP3773604B1 (en)
JP (2) JP7242696B2 (en)
ES (1) ES2949441T3 (en)
WO (1) WO2019191026A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017219878B2 (en) 2016-02-18 2022-12-22 Invirsa, Inc. Methods for the use of 5'-adenosine diphosphate ribose (ADPR)
EP3773604B1 (en) 2018-03-27 2023-04-19 Invirsa, Inc. Methods for the use of 5'-adenosine diphosphate ribose (adpr)
CN111714619B (en) * 2020-07-15 2023-03-14 上海市浦东新区人民医院 Application of fibroblast growth factor 6 in preparation of medicine for relieving liver injury of non-alcoholic steatohepatitis
CN112972453B (en) * 2021-03-05 2022-04-15 中国人民解放军军事科学院军事医学研究院 Application of MDL-800 in preparing medicine for inhibiting SARS-CoV-2 virus susceptibility

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04273826A (en) * 1991-02-27 1992-09-30 Dainippon Ink & Chem Inc Anti-rs viral agent
EP0618214A1 (en) 1993-04-01 1994-10-05 Merrell Dow Pharmaceuticals Inc. Unsaturated phosphonate derivatives of purines and pyrimidines
JPH07247210A (en) 1994-03-09 1995-09-26 Sunstar Inc Composition for oral cavity
WO1999012951A1 (en) 1997-09-11 1999-03-18 Oxigene, Inc. Uses of nicotinamide adenine dinucleotide and its analogs for treatment of malignant and infectious diseases
KR20010114214A (en) 1999-02-26 2001-12-31 인스파이어 파마슈티컬스 인코퍼레이티드 Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof
JP2003502033A (en) 1999-06-16 2003-01-21 アイコス コーポレイション Human poly (ADP-ribose) polyamylase 2 materials and methods
US6528042B1 (en) 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US20050009777A1 (en) 2001-07-25 2005-01-13 Mack Stephen Robert Non-natural carbon-linked nucleotides and dinucleotides
DE60325353D1 (en) 2002-05-21 2009-01-29 Abbott Lab TREATMENT OF MUCOSITIS
JP2005089450A (en) 2003-08-11 2005-04-07 Fujisawa Pharmaceut Co Ltd Prophylactic or therapeutic agent for infectious disease caused by rs virus
US20070212395A1 (en) 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
US20050276762A1 (en) * 2004-06-15 2005-12-15 Tapas Das Topical compositions containing 5'-adenosine-diphosphate ribose
EP1928440A2 (en) 2005-05-25 2008-06-11 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
EP1948215B1 (en) 2005-11-14 2012-01-11 Centre National De La Recherche Scientifique (Cnrs) MacroH2A non-histone domain as inhibitor of PARP-1 activity and uses thereof
WO2008154129A1 (en) 2007-06-08 2008-12-18 Bausch & Lomb Incorporated Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye
US20110217262A1 (en) 2010-03-05 2011-09-08 Kornfield Julia A Treatment of Ocular Surface Disorders by Increasing Conjunctival Vascular Permeability
CA2798697A1 (en) 2010-05-10 2011-11-17 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
BR112013028735A2 (en) 2011-05-12 2017-12-05 Foresight Biotherapeutics Inc stable povidone iodine compositions with steroids or non-steroidal anti-inflammatory drugs
US20160287622A1 (en) * 2013-11-18 2016-10-06 Massachusetts Institute Of Technology Compositions and methods for treating immune and viral disorders and modulating protein-rna interaction
AU2017219878B2 (en) * 2016-02-18 2022-12-22 Invirsa, Inc. Methods for the use of 5'-adenosine diphosphate ribose (ADPR)
EP3773604B1 (en) 2018-03-27 2023-04-19 Invirsa, Inc. Methods for the use of 5'-adenosine diphosphate ribose (adpr)

Similar Documents

Publication Publication Date Title
US5972904A (en) Method of treating sinusitis with uridine triphosphates and related compounds
EP0938322B1 (en) Use of uridine triphosphate related compounds for the prevention and treatment of pneumonia in immobilized patients
US6423694B1 (en) Method of treating otitis media with uridine triphosphates and related compounds
EP0889728B1 (en) Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
ES2222294T3 (en) OPTIMIZED FORMULATION OF TOBRAMYCIN FOR ADMINISTRATION IN THE FORM OF AEROSOL.
EP0941099B1 (en) Treatment of bronchitis with diuridine tetraphosphate
CN101495122A (en) Treprostinil administration using a metered dose inhaler
JP2014518268A5 (en)
WO1997035591A9 (en) Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
JP2023071933A5 (en)
JP2009500354A (en) P2Y6 receptor agonists for treating pulmonary diseases
CA2468344A1 (en) Methods and compositions for treating lesions of the respiratory epithelium
US6420347B1 (en) Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
TWI516283B (en) Compositions and methods for treating or preventing pneumovirus infection and associated diseases
JPWO2019191026A5 (en)
JP2019505596A5 (en)
RU2015129076A (en) Arylalkyl and Aryloxyalkyl-Substituted Compounds Blocking the Epithelial Sodium Channel
HRP20211942T1 (en) Methods for the use of 5'-adenosine diphosphate ribose (adpr)
TW202042813A (en) New formulations containing leukotriene receptor antagonists
CA2701388C (en) Calcium glycerophosphate for treating and preventing respiratory diseases or conditions
EP1941883A1 (en) Use of sodium blockers for an early therapy of obstructive lung diseases
KR100549904B1 (en) A pharmaceutical composition for treating ciliary dyskinesia, containing uridinde triphosphate and related compounds
CA3202852A1 (en) Methods and compositions for treating chronic obstructive pulmonary disease, asthma, pneumonia, bronchitis, cystic fibrosis and pulmonary edema, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, a cute respiratory distress syndrome, and pulmonary arterial hypertension
IT202000012343A1 (en) METHOTREXATE FOR USE IN THE PHARMACEUTICAL TREATMENT OF VIRAL RESPIRATORY TRACT INFECTIONS
TW505517B (en) Novel pharmaceutical compositions of uridine triphosphate